Skip to main content
main-content

The independent medical news service

Breast cancer

11-06-2021 | Oncology | Highlight | Article

Patient survey points to need for innovative dosing strategies in MBC

The high side-effect burden of metastatic breast cancer treatments warrants the development of innovative dosing strategies to maintain quality of life, suggest the results of an advocate-led survey of patients.

10-06-2021 | Oncology | News | Article

Long-term benefits to neoadjuvant durvalumab in triple-negative breast cancer

Adding the PD-L1 inhibitor durvalumab to neoadjuvant chemotherapy may improve survival outcomes in people with triple-negative breast cancer, show GeparNUEVO data presented at the 2021 ASCO Annual Meeting.

08-06-2021 | Oncology | News | Article

‘Excellent’ outcomes with de-escalated neoadjuvant early breast cancer regimen

A de-escalated neoadjuvant regimen of pertuzumab and trastuzumab plus paclitaxel leads to “excellent” pathologic complete response rates and survival in people with hormone receptor-negative, HER2-positive early breast cancer, phase 2 study findings indicate.

07-06-2021 | Oncology | News | Article

Lisinopril may prevent trastuzumab–anthracycline-related LVEF decline

Concurrent use of the ACE inhibitor lisinopril could help reduce the risk for left ventricular ejection fraction decline in women receiving trastuzumab and anthracyclines for HER2-positive early breast cancer, suggests US research.

07-06-2021 | Oncology | News | Article

Adding venetoclax to fulvestrant offers no extra benefit in VERONICA trial

Adding the BCL2 inhibitor venetoclax to fulvestrant does not improve outcomes for women with estrogen receptor-positive, HER2-negative locally advanced breast cancer resistant to endocrine and CDK4/6 inhibitor treatment, say the VERONICA investigators.

06-06-2021 | Oncology | News | Article

DAWNA-1 brings new CDK4/6 inhibitor into HR-positive advanced breast cancer space

The novel CDK4/6 inhibitor dalpiciclib plus fulvestrant could be “a new treatment option” for patients who have received prior endocrine therapy for hormone receptor-positive advanced breast cancer, say the DAWNA-1 investigators.

05-06-2021 | Oncology | News | Article

‘Meaningful benefit’ with adjuvant olaparib in BRCA-mutated early breast cancer

The OlympiA study has demonstrated a significant reduction in the risk for recurrence and disease progression with adjuvant olaparib versus placebo in patients with HER2-negative, early-stage breast cancer and germline BRCA mutations.

27-05-2021 | Oncology | News | Article

Imaging-guided chemotherapy omission shows QoL benefits in breast cancer

An 18F-fluorodeoxyglucose positron emission tomography response-adapted treatment strategy could lead to improved quality of life for some patients with HER2-positive, early-stage breast cancer, study findings indicate.

24-05-2021 | Oncology | News | Article

COVID-19 declines in breast cancer screening show sociodemographic inequities

The declines in breast cancer screening during the COVID-19 pandemic are more marked among women from minority communities and those living in rural areas, report US researchers.

13-05-2021 | Oncology | News | Article

FLIPPER QoL data support palbociclib–fulvestrant use in postmenopausal breast cancer patients

The quality of life of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer remains largely unchanged by the addition of palbociclib to first-line fulvestrant, suggest data from the FLIPPER trial.

12-05-2021 | Oncology | News | Article

Low cardiac event rates with dual HER2 blockade in early breast cancer

The BERENICE investigators report a low incidence of cardiac events with the use of pertuzumab–trastuzumab-based neoadjuvant and adjuvant regimens in patients with HER2-positive, early breast cancer after 5 years of follow-up.

12-05-2021 | Oncology | News | Article

Breast cancer HER2-low status evolution revealed

Paired analysis of primary and relapsed breast cancer specimens shows that many HER2-negative patients switch between HER2-low and HER2-0 expression during disease progression.

12-05-2021 | Oncology | News | Article

COVID-19 leaves large cancer screening deficit in USA

Breast, prostate, and colorectal cancer screening rates declined sharply during the initial months of the COVID-19 pandemic in the USA, and while they subsequently recovered, a large deficit remains, study findings indicate.

11-05-2021 | Oncology | News | Article

ShortHER update reassuring for patients who need to discontinue trastuzumab early

Long-term results from the ShortHER trial of adjuvant trastuzumab de-escalation provide reassurance for patients with HER2-positive, early breast cancer who may need to discontinue treatment before completing the standard 1-year course.

11-05-2021 | Oncology | News | Article

TROPION-PanTumor01 flags datopotamab deruxtecan potential for advanced TNBC

TROPION-PanTumor01 trial findings suggest that the TROP2-directed antibody–drug conjugate datopotamab deruxtecan might offer a novel treatment option for patients with advanced triple-negative breast cancer.

10-05-2021 | Oncology | News | Article

​​​​​​​Molecular risk may modify long-term endocrine therapy benefit in premenopausal breast cancer

The long-term benefit of endocrine therapy in premenopausal women with breast cancer may be influenced by molecular risk, suggest Swedish findings.

10-05-2021 | Oncology | News | Article

GELATO: Atezolizumab–carboplatin promising for metastatic lobular breast cancer

Early results from the GELATO trial point to the potential of atezolizumab plus carboplatin for the treatment of metastatic invasive lobular breast cancer.

06-05-2021 | Oncology | News | Article

TAPUR corroborates pembrolizumab benefit in TMB-high metastatic breast cancer

Heavily pretreated patients with metastatic breast cancer characterized by a high tumor mutational burden are likely to derive “meaningful clinical benefit” from pembrolizumab monotherapy, say the TAPUR researchers.

30-04-2021 | Oncology | News | Article

Breast conserving therapy may be an option for BRCA1/2 variant carriers

Individuals with breast cancer and a BRCA1/2 variant experience comparable survival rates whether they are treated with breast-conserving therapy or mastectomy with or without radiotherapy, Chinese researchers suggest.

28-04-2021 | Oncology | News | Article

AHA issues statement on managing hormonal therapy-related CVD risks

The American Heart Association has released a consensus statement on the management of cardiovascular disease in patients receiving hormonal therapies for breast or prostate cancer.

Image Credits